ArticleJapanese journal of gastroenterology and hepatology2025
Prognostic Factor and Serum Biomarker Changes in Non-Surgical Hepatocellular Carcinoma Patients Treated with Radioembolization.
Article in Japanese journal of gastroenterology and hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Dynamic Changes in Serum AFP, Albumin and ALBI after Radioembolization in Patients with Unresectable Hepatocellular Carcinoma with High or Low Alpha-Fetoprotein Levels.Japanese journal of gastroenterology and hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Background: 1.1:Transarterial radioembolization (TARE) with 90Y is a primary therapy for hepatocellular carcinoma (HCC), including patients with portal vein thrombosis (PVT). Patient survival subgroups post TARE have not been clearly defined. Aims: 1.2.To identify prognostic factors in patients treated with TARE. Methods: 1.3.Non-surgical HCC patients (n=116) were treated with TARE and prospectively followed for survival and changes in blood parameters relating to inflammation and tumor indices. Results: 1.4.Baseline parameters with the highest hazard ratios (HR>2) for survival were C-reactive protein, alpha-fetoprotein (AFP), maximum tumor diameter (MTD) and PVT. A 2-parameter prognostic model was developed, consisting of serum AFP and C-reactive protein, which was especially significant in patients with PVT. Temporal changes post TARE in ALBI and serum gamma glutamyl transferase (GGT) levels occurred in patients with both high and low serum AFP. A network phenotyping strategy (NPS) showed that patient phenotypes also change after TARE. Post TARE reduction in AFP or GGT or increase in albumin levels were associated with improved survival. Conclusions: 1.5.Changes in serum CRP, AFP, GGT, albumin, ALBI, and NPS phenotype occurred early after TARE. Changes in AFP, GGT and albumin related to survival and may be useful in selecting patients for additional treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.